coronaviru
diseas
initi
viral
replic
phase
often
follow
hyperinflammatori
reaction
lung
organ
system
cytokin
storm
syndrom
lead
acut
respiratori
distress
syndrom
ard
multiorgan
failur
deathdespit
maxim
support
care
prevent
hyperinflamm
key
avoid
progress
sever
stage
previous
demonstr
adrenerg
receptor
ar
antagonist
prevent
cytokin
storm
syndrom
result
death
mice
present
retrospect
studi
outcom
patient
acut
respiratori
distress
n
pneumonia
n
patient
acut
respiratori
distress
take
ar
antagonist
condit
reduc
risk
requir
ventil
reduc
risk
ventil
death
compar
nonus
adjust
ci
p
contrast
signific
effect
observ
betaadrenerg
receptor
antagonist
result
support
studi
ar
antagonist
prevent
ard
reduc
mortal
pneumonia
acut
respiratori
distress
well
highlight
need
prospect
trial
ar
antagonist
assess
efficaci
prevent
cytokin
storm
syndrom
death
million
peopl
contract
bacteri
viral
pneumonia
usual
overcom
local
immuneinflammatori
respons
sever
case
figur
organ
ultim
compromis
function
caus
high
morbid
mortal
diseasemodifi
strategi
condit
includ
target
viru
antivir
prevent
hyperinflamm
immunomodul
immunosuppressor
propos
approach
use
latter
strategi
hyperinflamm
prevent
special
cell
inflammatori
respons
commun
secret
peptid
call
cytokin
amplifi
immuneinflammatori
respons
restor
homeostasi
threat
reced
howev
hyperinflamm
cytokin
trigger
immun
cell
produc
even
cytokin
form
cytokin
storm
damag
healthi
tissu
overwhelm
host
patient
experi
cytokin
storm
syndrom
css
character
elev
proinflammatori
cytokin
includ
interleukin
il
tumor
necrosi
granulocytecoloni
stimul
factor
among
other
one
propos
immunosuppress
approach
amelior
css
block
signal
level
predict
sever
inhospit
mortal
monoclon
antibodi
siltuximab
receptor
tocilizumab
sarilumab
clinic
trial
css
howev
risk
suppress
antivir
host
respons
includ
prolong
immunosuppress
potenti
advers
reaction
like
restrict
antibodi
util
addit
prohibit
cost
anoth
prevent
approach
block
catecholamin
releas
preced
hyperinflamm
enhanc
inflammatori
injuri
augment
cytokin
product
via
selfamplifi
process
requir
adrenerg
receptor
ar
signal
mice
catecholamin
synthesi
inhibit
reduc
cytokin
respons
increas
surviv
inflammatori
stimuli
ar
antagonist
prazosin
clinic
realist
dosag
betaadrenerg
receptor
antagonistsoff
similar
protect
show
drug
class
prevent
cytokin
storm
preclin
find
provid
rational
clinic
studi
assess
whether
ar
antagonist
prevent
css
sequela
date
control
trial
studi
whether
ar
antagon
reduc
css
ard
mortal
patient
pneumonia
therefor
conduct
retrospect
analysi
two
cohort
hospit
patient
marketscan
research
databas
patient
take
ar
antagonist
treat
chronic
condit
unrel
ard
benign
prostat
hyperplasia
bph
hypertens
posttraumat
stress
disord
ptsd
claim
data
make
difficult
determin
take
prescrib
medic
defin
take
ar
antagonist
doxazosin
alfuzosin
prazosin
silodosin
terazosin
tamsulosin
fill
prescript
total
day
year
preced
hospit
due
transit
medicar
coverag
age
nine
time
men
women
use
ar
antagonist
due
bph
studi
men
estim
odd
ratio
adjust
odd
ratio
aor
use
logist
regress
relat
receipt
ar
antagonist
two
outcom
measur
progress
mechan
ventil
progress
inhospit
death
use
profil
maximum
likelihood
estim
confid
interv
ci
model
adjust
age
fiscal
year
prior
inpati
admiss
total
prior
day
inpati
comorbid
identifi
healthcar
encount
prior
year
hypertens
ischem
heart
diseas
acut
myocardi
infarct
heart
failur
chronic
obstruct
pulmonari
diseas
diabet
mellitu
ptsd
first
cohort
patient
diagnos
pneumonia
identifi
agenc
healthcar
research
qualiti
ahrq
pneumonia
categori
figur
cohort
found
take
ar
antagonist
compar
nonus
associ
lower
incid
mechan
ventil
p
lower
incid
ventil
death
p
second
cohort
compris
patient
diagnos
acut
respiratori
distress
code
often
precursor
ard
figur
cohort
take
ar
antagonist
compar
nonus
associ
lower
incid
mechan
ventil
p
lower
incid
ventil
death
p
diagnos
cohort
antagonist
use
affect
either
clinic
outcom
fig
next
specif
assess
commonli
use
ar
antagonist
tamsulosin
select
receptor
subtyp
tamsulosin
use
almost
exclus
bph
thu
reduc
likelihood
confound
indic
pneumonia
patient
take
ar
antagonist
receiv
tamsulosin
prazosin
among
acut
respiratori
distress
patient
proport
respect
found
figur
pneumonia
patient
take
tamsulosin
lower
incid
mechan
ventil
compar
nonus
ar
antagonist
lower
incid
ventil
death
p
p
respect
acut
respiratori
distress
patient
take
tamsulosin
lower
incid
mechan
ventil
lower
incid
ventil
death
p
p
respect
state
result
robust
multipl
propens
weight
approach
doubli
robust
method
causal
forest
result
retrospect
clinic
studi
extend
preclin
find
support
hypothesi
ar
antagonist
may
reduc
morbid
mortal
patient
risk
develop
cytokin
storm
syndrom
random
prospect
trial
need
test
hypothesi
specif
patient
risk
cytokin
storm
due
trial
earli
administr
ar
antagonist
prior
develop
sever
symptom
requir
goal
prevent
rather
treat
hyperinflamm
